Company updateMoneycontrol
Buy Natco Pharma: target of Rs 1065: ICICI Securities
Positive+39
GreyOak summary
ICICI Securities upgraded Natco Pharma to a BUY rating with a target price of Rs 1,065. The firm noted that Q2FY27 performance exceeded expectations despite the loss of gRevlimid exclusivity, driven by a 32.7% sequential jump in formulations sales and an 80% surge in Brazil sales.
What it affects
- Natco PharmaNATCOPHARMPositive +39
Rating upgraded to BUY with target Rs 1065.Rolling sentiment Negative -54
Source
Read the original at MoneycontrolMore Natco Pharma news
- Natco Pharma shares rally 9% despite weak Q2 resultsNDTV Profit · Results ·
- Natco Pharma Q2 profit drops 60.8% to ₹202.6 crBusiness Standard · Results ·
- Natco Pharma Q2 profit, revenue fall; dividend declaredCNBC-TV18 · Results ·
- Natco Pharma Q2 Profit Falls 61% to Rs 203 CrNDTV Profit · Results ·